Finerenone added to RAS/SGLT2 blockade for non-diabetic chronic kidney disease. Results of a preclinical double-blinded randomized controlled trial.

The goal of this study was to compare Next Generation mRNA (RNA-seq) data obtained from whole kidney tissue from WT and untreated, Ramipril treated, and Ramipril/Empagliflozin treated, and Ramipril/Empagliflozin/Finerenone treated Col4a3-/- mice in the 129/SvJ background. Overall design: Comparison in WT vs Col4a3-/- Vehicle, Col4a3-/- Vehicle vs Ramipril/Empagliflozin/Finerenone, Col4a3-/- Ramipril vs Ramipril/Empagliflozin/Finerenone, and Col4a3-/- Ramipril/Empagliflozin vs Ramipril/Empagliflozin/Finerenone kidneys of RNA expression of significantly altered canonical pathways.